Product Development Advisory Committee

The Product Development Advisory Committee (PDAC) provides expertise to the Oversight Committee on the growing gap between translational discovery and later stage clinical development of new oncology drugs in Texas. Primarily, it is making recommendations on the breadth of life science expertise needed in Texas to advance the state’s ability to improve cancer patient outcomes from promising scientific discoveries. 

Members:

Andrew Strong, JD, Chair
Partner, Pillsbury Winthrop Shaw Pittman, LLP
Founding CEO & President, Kalon Biotherapeutics

Michele Park, Ph.D., Vice-Chair
Former Partner
Clarus Funds

Claire Aldridge, Ph.D.
Associate Vice President, Commercialization and Business Development
The University of Texas Southwestern Medical Center

David Arthur
CEO and Director
Salarius Pharmaceuticals

Bruce Butler, Ph.D.
Vice President, Research and Technology
Director, Office of Technology Management
UT Health Sciences Center at Houston

Julie Goonewardene
Associate Vice Chancellor for Innovation and Strategic Investment
The University of Texas System

Greg Hartman
Vice Chancellor for Strategic Initiatives
Office of Strategic Initiatives
Texas A&M University System

Paul Lammers, M.D.
CEO, President and Director, Triumvira Immunologics
Former CEO and President, Mirna Therapeutics

David Lowe, Ph.D.
Co-Founder, Aeglea Biotherapeutics
Managing Director, AllosteRx Capital

Jonathan MacQuitty, Ph.D.
Venture Partner
Lightspeed Venture Partners

Dennis McWilliams
Venture Partner
Sante Ventures

Tracy Saxton, Ph.D.
CEO, Lengo Therapeutics
Adviser, Frazier Healthcare Partners

Emma Schwartz
President
Medical Center of the Americas Foundation

Greg Stein, M.D.
CEO
Curtana Pharmaceuticals

Ann Tanabe
CEO
BioHouston, Inc.

Ilia Tikhomirov
President and CEO
Formation Biologics

Matt Winkler, Ph.D.
Founder, Asuragen
Founder, Mirna Therapeutics